Allogeneic stem cell transplantation for myelofibrosis in 2012.
about
Guidelines for the management of myeloproliferative neoplasmsClinical potential of pacritinib in the treatment of myelofibrosisSafety evaluation of ruxolitinib for treating myelofibrosis.Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCTAllogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party oMPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosisJanus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosisComprehensive review of JAK inhibitors in myeloproliferative neoplasms.Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.Blood stem cell products: toward sustainable benchmarks for clinical translation.Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.Treatment and management of myelofibrosis in the era of JAK inhibitorsAllogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits?Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.Pacritinib: a new agent for the management of myelofibrosis?New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.Myeloproliferative neoplasm stem cells.Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?Splenectomy prior to allogeneic hematopoietic SCT increases the risk of post-transplant lymphoproliferative disease.Recent advances in the diagnosis and management of primary myelofibrosis.Safety and outcome of allogeneic stem cell transplantation in myelofibrosis.
P2860
Q26778326-38C3F325-49FF-42B4-8927-2E20C91A91C1Q26796450-C045160F-122F-42F1-90CF-5AC84D04BDD2Q33415731-DA523977-52C2-4A9B-98DA-40EE4F69D5CAQ33416494-7379C324-60B2-4B3F-8D31-D626B7FBEEBEQ33556843-1A3D0A21-2F53-478D-BB13-194913F284D3Q33558748-23A88905-C6B0-4AB1-8227-970E3EBCB948Q34047897-A2A28290-95D0-43A0-AC1A-D9D487440479Q35735663-C5FC5A4E-0F8B-49E9-80BE-BBEF37085BF0Q36776428-28195531-9750-4AAB-8526-B4871CF02E52Q37272164-4BA1C0F9-D819-4B02-95E3-E3AAB2289AEDQ38072649-B3764E29-B87D-49CB-BEB2-CAFED70EE6F9Q38100790-B19F6EFD-BEF8-4544-8D96-1A683C587696Q38132739-B277995B-803A-457B-98C7-C98FEC53180DQ38174781-156EA4D7-F83B-4C24-B265-3ACA1077B774Q38444153-14A0AA6E-3457-4140-9BB3-46F15F88F94CQ38590232-7761E8DC-052A-4BEA-A982-FD05952EC2F5Q38924189-21B50A9B-553D-4702-ADDE-9180A9BE88DCQ39118859-1B954AA8-4B64-4D9E-9B5F-79183A2B6A37Q41519713-D4CAAF38-9E49-4BFB-B9A9-833C680B7ADBQ46990862-303BA3B0-1D73-4A41-8B29-784C2B94902FQ54443654-7F8AB98C-4E94-4AC8-B531-24AD6F766FDCQ54980872-EBF8CD97-ADA5-400E-8F6C-99C17A9C4B6FQ55060741-0EEF71D7-3E92-419E-88D4-F609440DAE2B
P2860
Allogeneic stem cell transplantation for myelofibrosis in 2012.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Allogeneic stem cell transplantation for myelofibrosis in 2012.
@en
Allogeneic stem cell transplantation for myelofibrosis in 2012.
@nl
type
label
Allogeneic stem cell transplantation for myelofibrosis in 2012.
@en
Allogeneic stem cell transplantation for myelofibrosis in 2012.
@nl
prefLabel
Allogeneic stem cell transplantation for myelofibrosis in 2012.
@en
Allogeneic stem cell transplantation for myelofibrosis in 2012.
@nl
P2093
P2860
P1476
Allogeneic stem cell transplantation for myelofibrosis in 2012.
@en
P2093
Claire N Harrison
Donal P McLornan
Graham Jackson
P2860
P304
P356
10.1111/J.1365-2141.2012.09107.X
P407
P50
P577
2012-03-29T00:00:00Z